Atenolol (beta-blocker)

Atenolol is a selective beta-1 adrenergic receptor blocker that has become an important medication in avian cardiology for the management of various cardiac arrhythmias and heart rate abnormalities in birds. This medication belongs to the class of drugs commonly known as beta-blockers, which work by blocking the effects of adrenaline and related stress hormones on the heart. Atenolol is classified as a cardioselective beta-blocker, meaning it preferentially affects the heart rather than other organs containing beta receptors, which can reduce certain side effects. In avian medicine, atenolol has proven valuable for treating birds with abnormally rapid heart rates, certain types of arrhythmias, and occasionally as part of combination therapy for hypertension and other cardiovascular conditions.

The mechanism of action of atenolol involves blocking beta-1 adrenergic receptors located primarily in cardiac tissue. When these receptors are stimulated by catecholamines such as adrenaline, they increase heart rate, strengthen cardiac contractions, and speed electrical conduction through the heart. By blocking these receptors, atenolol reduces heart rate, decreases the force of cardiac contractions, and slows conduction through the atrioventricular node. These effects make atenolol particularly useful for controlling rapid heart rhythms and reducing the heart's workload. The duration of action is relatively long, typically allowing for once or twice daily dosing depending on the specific condition being treated and the individual patient's response.

Atenolol is available commercially as tablets intended for human use, but avian patients typically require compounded formulations due to their small body size and the need for precise dosing. Compounding pharmacies can prepare oral suspensions or capsules in concentrations appropriate for avian patients, allowing for accurate measurement of the small doses required. Administration is usually oral, with the medication given directly into the mouth or crop using a syringe, or occasionally mixed with food for birds that accept this method. The consistency of administration timing is particularly important with beta-blockers, as irregular dosing can lead to fluctuations in heart rate control and potentially trigger rebound effects.

The safety profile of atenolol in birds requires careful consideration, as beta-blockers have significant effects on cardiovascular function that must be balanced against therapeutic benefits. When used appropriately under veterinary supervision, atenolol can effectively manage cardiac conditions while maintaining acceptable safety margins. However, the medication's cardiac effects mean that improper dosing or use in inappropriate patients can have serious consequences. Thorough cardiac evaluation, including physical examination and often echocardiography and electrocardiography, should precede atenolol therapy to ensure the medication is appropriate for the specific cardiac condition present. Regular monitoring during treatment helps ensure continued safety and efficacy, and bird owners should never adjust atenolol dosing without veterinary guidance.

The primary indication for atenolol in avian medicine is the management of tachyarrhythmias, which are abnormal heart rhythms characterized by excessively rapid heart rates. Birds normally have faster heart rates than mammals of similar size, but various cardiac conditions can cause heart rates to become pathologically elevated or irregular. Supraventricular tachycardias, including atrial fibrillation and atrial flutter, may respond to atenolol therapy through the medication's ability to slow conduction through the atrioventricular node and reduce the ventricular response rate. By controlling the heart rate, atenolol helps improve cardiac efficiency and reduces symptoms associated with rapid, irregular heart rhythms. The medication is often considered a first-line treatment option for rate control in birds with various supraventricular arrhythmias.

Atenolol is also used for birds with ventricular arrhythmias in certain circumstances, though the approach to these rhythm disturbances is more complex. Premature ventricular contractions and ventricular tachycardia may be treated with beta-blockers when the underlying mechanism involves excessive catecholamine stimulation or when other antiarrhythmic approaches are not suitable. The decision to use atenolol for ventricular arrhythmias requires careful cardiac evaluation and consideration of the specific arrhythmia mechanism. In some cases, atenolol may be combined with other antiarrhythmic medications for optimal rhythm control. The avian cardiologist or veterinarian with cardiac expertise will determine the most appropriate treatment approach based on the specific arrhythmia characteristics and underlying cardiac condition.

Secondary uses of atenolol in avian medicine include hypertension management, particularly when combined with other antihypertensive agents for enhanced blood pressure control. While calcium channel blockers like amlodipine are often preferred as first-line agents for avian hypertension, atenolol may be added to the treatment regimen when single-agent therapy provides insufficient blood pressure reduction. The heart rate-lowering effect of atenolol can be beneficial in hypertensive birds that also have elevated heart rates, addressing both aspects of cardiovascular dysfunction. Additionally, atenolol may help reduce the cardiac workload in hypertensive patients by decreasing the force of cardiac contractions.

Atenolol may be prescribed for birds with certain types of cardiomyopathy, particularly hypertrophic cardiomyopathy where the heart muscle has become abnormally thickened. In these cases, beta-blockade can help improve cardiac filling by slowing the heart rate and allowing more time for ventricular relaxation between beats. The reduced force of contraction may also decrease the degree of outflow obstruction in some forms of hypertrophic cardiomyopathy. However, the use of beta-blockers in cardiomyopathy requires careful patient selection and monitoring, as these medications can worsen heart failure in some patients with compromised cardiac function.

When selecting atenolol for an avian patient, veterinarians consider the specific cardiac condition, the desired therapeutic effects, and patient factors that may influence drug response or tolerance. Atenolol is often chosen for its cardioselectivity, which theoretically reduces the risk of bronchospasm and other effects mediated by beta-2 receptors in the lungs and peripheral vasculature. The medication's relatively predictable pharmacokinetics and once or twice daily dosing schedule make it practical for long-term management of chronic cardiac conditions. For birds requiring ongoing heart rate control or arrhythmia management, atenolol offers an effective and generally well-tolerated therapeutic option when used under appropriate veterinary supervision.

Dosing of atenolol in avian patients requires careful individualization by an experienced avian veterinarian or avian cardiologist, as the appropriate dose depends on the specific cardiac condition being treated, the bird's body weight, species-specific factors, and individual response to the medication. Beta-blockers have significant effects on cardiovascular function, and dosing must be precise to achieve therapeutic benefit while avoiding excessive cardiac depression. The avian veterinarian will calculate the dose based on the bird's accurate body weight and will select a formulation that allows for precise measurement of the small doses typically required for avian patients. Bird owners should never attempt to determine atenolol dosing independently or extrapolate doses from other species.

General dosing guidelines for atenolol in birds typically range from 0.5 to 2 milligrams per kilogram of body weight, administered once or twice daily depending on the condition being treated and the individual patient's response. Initial dosing usually starts at the lower end of the range, with gradual titration upward as needed to achieve the desired therapeutic effect. The target heart rate or level of arrhythmia control guides dose adjustments, and achieving optimal dosing may require several adjustment visits. Some birds may require doses outside the typical range, either lower due to sensitivity or higher to achieve adequate therapeutic effect. The dosing frequency depends on the medication's duration of effect in the individual patient and the consistency of heart rate control achieved.

Treatment duration with atenolol varies depending on the underlying cardiac condition and whether the arrhythmia or heart rate abnormality is acute or chronic. Many birds with cardiac arrhythmias require long-term or lifelong atenolol therapy to maintain heart rate control. Treatment protocols include regular reassessment appointments where the avian veterinarian evaluates heart rate, rhythm, and overall cardiac status. Electrocardiography may be performed periodically to assess arrhythmia control. Some birds may achieve sufficient improvement to allow dose reduction, while others may require dose increases over time as their cardiac condition evolves. The decision to continue, adjust, or discontinue atenolol therapy should always be made in consultation with the veterinarian.

Administering atenolol to birds requires careful technique and consistent timing to maintain stable blood levels and consistent heart rate control. Compounded oral suspensions are commonly used for avian patients, and the suspension should be mixed well before each use to ensure uniform drug distribution. The medication can be administered directly into the mouth or crop using an appropriately sized syringe. Some birds may accept the medication mixed with a small amount of favored food, though owners must ensure complete consumption of the medicated portion. Maintaining consistent timing of administration is particularly important with beta-blockers, as missed or late doses can result in fluctuations in heart rate control. The medication should be given at approximately the same time each day.

If a dose of atenolol is missed, bird owners should contact their avian veterinarian for guidance on how to proceed, as the appropriate response may depend on how much time has elapsed and the bird's specific cardiac condition. In general, if a dose is remembered within a few hours of the scheduled time, it may be given late. If it is close to the time for the next scheduled dose, the missed dose is typically skipped. Doubling doses to make up for missed medication should never be done, as this can cause excessive heart rate reduction and potentially dangerous bradycardia. Getting back on a regular schedule as quickly as possible helps maintain consistent therapeutic effect.

Abrupt discontinuation of atenolol should be avoided, as stopping beta-blocker therapy suddenly can cause rebound tachycardia, worsening of arrhythmias, or other adverse cardiovascular effects. When discontinuation is appropriate, the avian veterinarian will typically recommend a gradual dose reduction over days to weeks, depending on the duration of treatment and the bird's cardiac status. Bird owners should never stop atenolol without veterinary guidance, even if the bird appears to be doing well or if side effects are suspected. Any concerns about the medication should be discussed with the avian veterinarian, who can provide appropriate guidance on dose adjustment or alternative medications if needed.

Atenolol is generally well-tolerated by many avian patients when used at appropriate doses under proper veterinary supervision, but as a medication with significant cardiovascular effects, side effects can occur and require monitoring. The most common side effects are related to the medication's intended pharmacological action of reducing heart rate and cardiac contractility. Understanding potential adverse effects allows bird owners to monitor their birds appropriately during treatment and recognize when veterinary consultation is needed. Most side effects are dose-dependent, meaning they are more likely to occur at higher doses or in birds that are particularly sensitive to beta-blockade.

Common and typically mild side effects of atenolol in birds may include reduced activity level or mild lethargy, which can result from the medication's heart rate-lowering effect. Some birds may show decreased appetite, particularly when treatment is first initiated. Mild weakness or reduced stamina may be observed as the cardiovascular system adjusts to beta-blockade. These effects are often transient and improve as the bird adapts to the medication over the first weeks of treatment. Bird owners should monitor for these changes and report them to the avian veterinarian, but mild, stable effects are not necessarily cause for alarm unless they persist or worsen significantly.

More significant side effects that warrant closer attention include pronounced bradycardia (excessively slow heart rate), which can cause weakness, exercise intolerance, collapse, or other signs of inadequate cardiac output. Beta-blockers can also worsen heart failure in some patients by reducing the heart's pumping ability, so birds should be monitored for signs of fluid retention, respiratory difficulty, or declining activity tolerance. Hypotension (low blood pressure) may occur, particularly when atenolol is combined with other cardiovascular medications, and can manifest as weakness or unsteadiness. If these more significant effects are observed, the avian veterinarian should be contacted promptly, as dose adjustment or medication change may be necessary.

Serious side effects requiring immediate veterinary attention include severe bradycardia causing collapse or loss of consciousness, severe respiratory difficulty that could indicate heart failure exacerbation, or complete heart block. Allergic reactions are rare but can occur with any medication. Signs of a severe adverse reaction include acute onset of weakness, respiratory distress, facial swelling, or dramatic behavioral changes. Any sudden deterioration in the bird's condition during atenolol treatment should be treated as a potential emergency requiring immediate veterinary evaluation. Beta-blockers can also mask signs of hypoglycemia in diabetic birds, which is a consideration if the bird has concurrent metabolic disease.

Rare side effects and long-term considerations with atenolol therapy include potential effects on glucose metabolism, which may be relevant for birds with diabetes or metabolic disorders. Cold extremities, while difficult to assess in birds, could theoretically occur due to peripheral vasoconstriction. Long-term beta-blocker therapy requires periodic reassessment to ensure continued appropriateness and to monitor for any emerging adverse effects. Birds on chronic atenolol treatment should have regular veterinary check-ups including cardiac evaluation. Bird owners should maintain open communication with their avian veterinarian about any changes observed during treatment, as early detection of problems allows for prompt intervention. When in doubt about whether an observed change is medication-related, consulting the prescribing veterinarian is always advisable.

Atenolol should not be used in birds with known hypersensitivity or allergy to atenolol or other beta-adrenergic blocking agents. While allergic reactions to beta-blockers are uncommon, any bird that has experienced an adverse reaction to this class of medications should not receive atenolol. Cross-reactivity may exist between different beta-blockers, so birds with documented sensitivity to one medication in this class should be treated with alternative agents. Providing the avian veterinarian with a complete history of any previous medication reactions is essential for safe prescribing decisions and helps prevent potentially serious adverse events.

Significant bradycardia (slow heart rate) or heart block represents a major contraindication to atenolol use, as the medication's heart rate-lowering effect would further worsen these conditions. Birds with sick sinus syndrome, second or third-degree atrioventricular block, or other conditions characterized by inadequate heart rate should not receive beta-blockers unless they have a functioning pacemaker, which is rarely applicable in avian patients. The avian veterinarian will assess heart rate and rhythm through physical examination and often electrocardiography before prescribing atenolol to identify any conduction abnormalities that would preclude its use. If beta-blockade is needed but significant bradycardia exists, alternative treatments must be considered.

Uncompensated heart failure is a contraindication to initiating beta-blocker therapy, as the medication's negative inotropic effect (reduction in cardiac contractility) can worsen heart failure symptoms. Birds showing signs of decompensated heart failure such as respiratory difficulty from pulmonary edema, ascites, or severe exercise intolerance should have their heart failure stabilized before beta-blocker therapy is considered. Once heart failure is compensated with appropriate diuretic and other therapy, careful introduction of low-dose beta-blockers may be beneficial in some patients, but this requires expert cardiac assessment and close monitoring. The decision to use beta-blockers in birds with any degree of heart failure requires careful consideration of risks and benefits.

Other contraindications and precautions for atenolol include severe hypotension, where further blood pressure reduction from beta-blockade could be dangerous. Birds with pheochromocytoma should not receive beta-blockers without prior alpha-blockade due to the risk of hypertensive crisis. Caution is warranted in birds with respiratory disease, although atenolol's cardioselectivity reduces the risk of bronchospasm compared to non-selective beta-blockers. Very young birds, geriatric birds, and those with significant liver or kidney disease may require dose adjustments or enhanced monitoring. Birds that are severely debilitated, dehydrated, or in shock should be stabilized before atenolol is considered. Complete disclosure of the bird's medical history helps the avian veterinarian make informed decisions about the appropriateness of atenolol therapy.

Comprehensive disclosure of all medications, supplements, and treatments the bird is receiving is essential before starting atenolol therapy. Beta-blockers interact with numerous other drugs, and these interactions can affect both the safety and efficacy of treatment. Drug interactions may result in enhanced effects leading to toxicity, reduced effects leading to treatment failure, or unpredictable responses. Even supplements and over-the-counter products can interact with atenolol, so bird owners should provide their avian veterinarian with a complete list of everything the bird is receiving. This information allows for safe prescribing and appropriate monitoring during treatment.

Atenolol interacts significantly with other cardiovascular medications, and these combinations require careful management. When used with calcium channel blockers such as diltiazem or verapamil, additive effects on heart rate and cardiac conduction can occur, potentially leading to severe bradycardia or heart block. Combining atenolol with other antihypertensive agents can produce excessive blood pressure reduction. Concurrent use of digoxin with atenolol increases the risk of bradycardia, and digoxin levels may be affected. While combination cardiovascular therapy is sometimes necessary and beneficial, it requires careful dose adjustment and enhanced monitoring. The avian cardiologist or veterinarian will determine appropriate combinations and doses based on the individual patient's needs.

Certain other drug classes interact with beta-blockers in clinically important ways. Non-steroidal anti-inflammatory drugs may reduce the antihypertensive effect of atenolol by promoting sodium and fluid retention. Insulin and oral hypoglycemic agents may have altered effects in the presence of beta-blockers, as these medications can mask signs of hypoglycemia and affect glucose metabolism. Anesthetic agents may have enhanced cardiovascular depressant effects when combined with beta-blockers, which is important to communicate if the bird requires anesthesia for any procedure. Clonidine discontinuation in a patient also receiving beta-blockers can cause rebound hypertension, though this specific interaction is uncommon in avian medicine.

Monitoring for drug interactions during atenolol therapy involves regular cardiac assessment including heart rate evaluation and periodic electrocardiography when indicated. Signs that a drug interaction may be occurring include unexpected changes in heart rate control, emergence of new arrhythmias, development of heart failure symptoms, or changes in the bird's response to other medications. Bird owners should contact their avian veterinarian before giving any new medications or supplements to birds receiving atenolol. If new medications are added to the treatment regimen, the veterinarian will consider potential interactions and adjust doses or monitoring frequency appropriately. Maintaining an accurate medication list and promptly reporting any observed changes helps ensure safe and effective management of birds on beta-blocker therapy.

General precautions for atenolol use in birds emphasize the importance of accurate cardiac diagnosis before initiating therapy and careful monitoring throughout treatment. Beta-blockers have significant effects on cardiovascular function, and their use requires precise dosing based on accurate body weight and appropriate patient selection. The avian veterinarian should perform a thorough cardiac evaluation, which may include electrocardiography and echocardiography, to characterize the cardiac condition and ensure that beta-blockade is appropriate. Bird owners should follow dosing instructions exactly and maintain consistent timing of administration. Any deviation from the prescribed protocol should only occur after consultation with the veterinarian.

Species-specific considerations are important when using atenolol in birds, as different species may show varying sensitivity to beta-blockade. While cardiac conditions are most commonly recognized and treated in psittacines, other bird species may also require beta-blocker therapy. The cardiovascular physiology of birds differs from mammals in several important ways, including higher baseline heart rates and different autonomic regulation of cardiac function. These differences mean that responses to beta-blockers may not always follow patterns seen in mammalian species. When treating species with limited published information on beta-blocker use, enhanced monitoring and conservative dosing approaches are advisable.

Environmental and handling precautions during atenolol treatment include ensuring medications are stored securely and administered safely. Compounded liquid formulations should be kept away from children and other pets. Stress should be minimized during medication administration, as stress-induced catecholamine release might temporarily counteract beta-blocker effects or cause unpredictable cardiovascular responses. Creating a calm, routine approach to medication administration benefits both the bird and the accuracy of treatment delivery. Hands should be washed after handling the medication, and any spills should be cleaned promptly.

Monitoring during atenolol treatment should include regular assessment of heart rate and rhythm to evaluate therapeutic response. Bird owners should observe their birds daily for signs of excessive heart rate reduction, such as weakness, lethargy, or reluctance to move. Signs of efficacy include appropriate heart rate control and reduction or resolution of arrhythmia-related symptoms. Signs suggesting the dose may be too high include pronounced lethargy, weakness, or respiratory changes suggesting heart failure. Any concerns about the bird's response to treatment should prompt consultation with the avian veterinarian. Keeping a daily log of observations can help identify trends and provide valuable information at follow-up appointments.

Special populations requiring enhanced precautions include geriatric birds, who may be more sensitive to cardiac medications due to age-related changes in drug metabolism and cardiovascular function. Juvenile birds may also respond differently to beta-blockers. Birds with concurrent diseases, particularly hepatic or renal insufficiency, may require dose adjustments due to altered drug metabolism and elimination. Diabetic birds require monitoring for masked hypoglycemia symptoms, as beta-blockers can interfere with the normal warning signs of low blood sugar. Birds with respiratory disease should be monitored closely, although atenolol's cardioselectivity reduces respiratory risks compared to non-selective beta-blockers. Throughout treatment, maintaining communication with the avian veterinarian ensures that concerns are addressed promptly and treatment can be adjusted as needed.

Proper storage of atenolol maintains the medication's stability and effectiveness throughout the treatment period. Commercial atenolol tablets should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit (20 to 25 degrees Celsius), protected from heat, moisture, and direct light. The medication should remain in its original container with the cap securely closed to protect it from environmental factors. Storage location should be consistent and away from areas prone to temperature fluctuation or humidity, such as bathrooms, kitchens near stoves, or areas near windows. For compounded formulations commonly used in avian medicine, storage requirements may differ based on the specific formulation, and the compounding pharmacy will provide appropriate storage instructions.

Compounded atenolol suspensions require careful attention to storage and handling to ensure consistent potency throughout use. These formulations often have shorter expiration periods than commercial products, and the expiration date should be clearly noted and respected. Some compounded suspensions may require refrigeration while others are stable at room temperature, depending on the base vehicle and preservatives used. Before each use, liquid formulations should be gently but thoroughly mixed to ensure uniform distribution of medication throughout the suspension. Visual inspection before each dose helps identify any changes in appearance, color, or consistency that might indicate degradation. Any suspension showing unusual changes should not be used, and the compounding pharmacy should be contacted for guidance.

Safe handling and proper disposal of atenolol protects household members and the environment. The medication should be stored where children, other pets, and the bird cannot accidentally access it. When administering the medication, care should be taken to avoid spillage, and any spills should be cleaned up promptly. Hands should be washed after handling the medication. When atenolol is no longer needed due to treatment completion, expiration, or change in therapy, it should be disposed of properly rather than flushed or discarded in regular trash. Community drug take-back programs provide safe disposal options for unused medications. Pharmacies may offer guidance on proper disposal methods, and compounding pharmacies can advise specifically on their formulations. Maintaining security of cardiac medications and ensuring proper disposal demonstrates responsible medication management.

The response to atenolol can vary among different bird species, reflecting differences in cardiovascular physiology, drug metabolism, and sensitivity to beta-adrenergic blockade. Birds have fundamentally different cardiovascular characteristics compared to mammals, including higher heart rates relative to body size, different autonomic balance, and unique cardiac anatomy. These differences influence how individual species respond to beta-blocker therapy and underscore the importance of species-specific knowledge in treatment planning. Avian veterinarians and cardiologists draw upon published literature, clinical experience, and pharmacological principles when developing treatment protocols for different avian species.

Psittacine birds, including parrots, macaws, cockatoos, and related species, represent the group most commonly treated with atenolol due to the frequency of recognized cardiac conditions in these species. Psittacines commonly develop atherosclerosis, arrhythmias, and other cardiovascular diseases that may benefit from beta-blocker therapy. Experience with atenolol use in psittacines provides guidance for initial dosing, though individual variation means that dose titration is typically necessary. African grey parrots and Amazon parrots are particularly prone to cardiac conditions and may require careful cardiac management with medications including beta-blockers. Regular monitoring through electrocardiography and echocardiography helps guide therapy in psittacine patients.

Other bird groups, including passerines such as finches and canaries, raptors, and various other species, may occasionally require beta-blocker therapy but have less established dosing information. These species have different baseline heart rates, metabolic rates, and potentially different sensitivity to beta-adrenergic blockade. When treating non-psittacine species with atenolol, conservative initial dosing with careful upward titration helps minimize the risk of adverse effects while working toward therapeutic goals. Enhanced monitoring for both efficacy and toxicity is advisable when experience with a particular species is limited. Consultation with avian cardiologists or specialists familiar with diverse species can provide valuable guidance in these cases.

Size considerations significantly influence atenolol therapy, as the appropriate dose varies with body weight while the practical aspects of drug delivery differ based on bird size. Large psittacines may tolerate relatively standard formulations, while small birds require more concentrated or dilute preparations to allow accurate dosing. Accurate weighing is essential, and doses should be recalculated if the bird's weight changes significantly during treatment. Compounding pharmacies can prepare atenolol formulations in various concentrations suited to birds of different sizes. The avian veterinarian will select an appropriate formulation and provide precise dosing instructions tailored to the individual patient's size and needs.

Other beta-blockers represent alternatives to atenolol within the same pharmacological class, though availability and experience in avian medicine vary. Propranolol is a non-selective beta-blocker that has been used in birds, affecting both beta-1 receptors in the heart and beta-2 receptors in the lungs and vasculature. The non-selectivity of propranolol may provide different therapeutic effects but also carries increased risk of bronchoconstriction and other beta-2-mediated side effects. Metoprolol is another cardioselective beta-blocker similar to atenolol that may be used in avian patients. The choice between different beta-blockers depends on the specific clinical situation, available formulations, and clinician experience. Avian cardiologists can provide guidance on appropriate beta-blocker selection for individual patients.

Different classes of cardiovascular medications offer alternative or complementary approaches to cardiac conditions treated with atenolol. Calcium channel blockers such as diltiazem provide rate control through a different mechanism and may be preferred for certain arrhythmias or used in combination with beta-blockers. Digoxin offers positive inotropic effects along with rate-controlling properties for birds with heart failure and certain arrhythmias. Antiarrhythmic medications from other classes may be appropriate for specific arrhythmia types that do not respond adequately to beta-blockade. For hypertension, angiotensin-converting enzyme inhibitors or amlodipine provide alternative mechanisms of blood pressure control. The avian veterinarian or cardiologist will select the most appropriate medication or combination based on the specific cardiac diagnosis.

Complementary supportive measures may accompany atenolol therapy to optimize cardiac health in avian patients. Dietary modification to reduce sodium intake and maintain appropriate body weight can support cardiovascular function. Environmental management to reduce stress helps minimize catecholamine release that can trigger arrhythmias or increase cardiac workload. For birds with underlying atherosclerosis, addressing dietary fat content and providing opportunities for exercise supports overall cardiovascular health. Any complementary approaches should be discussed with and approved by the avian veterinarian to ensure compatibility with cardiac medication therapy. Bird owners should never substitute alternative treatments for prescribed beta-blocker therapy without professional guidance, as cardiac conditions require appropriate medical management for optimal outcomes.